Avalon GloboCare is an investment gem because it is brewing a highly diversified pipeline of potential blockbusters.
Leveraging precision medicine, Avalon employs liquid biopsy with exosomes biomarkers to provide an accurate diagnosis for various cancers and even nonalcoholic steatohepatitis.
The crown jewel of the immunotherapy franchise is a premier multi-target CAR-T. It has the power to circumvent prior limitations of the first generation drugs (Yescarta and Kymriah).
Remarkably, Avalon is cutting into the gargantuan regenerative medicine market as it harnesses the power of stem cell-derived exosomes.
With unique infrastructure and research programs, Avalon is positioned for colossal growth ahead. The financials and valuation indicate highly asymmetric rewards to risks profile.
Source (Full Article): https://seekingalpha.com/article/4271992-avalon-globocare-trifecta-biotech